Market Cap
CA$1.7b
Last Updated
2019/10/24 00:41 UTC
Data Sources
Company Financials +
Executive Summary
Aphria Inc. produces and sells medical cannabis in Canada and internationally.
Snowflake
Fundamentals
Fair value with mediocre balance sheet.
Similar Companies
Share Price & News
How has Aphria's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
2.8%
APHA
-2.1%
CA Pharmaceuticals
-0.3%
CA Market
1 Year Return
-59.1%
APHA
-46.2%
CA Pharmaceuticals
4.8%
CA Market
Return vs Industry: APHA underperformed the Canadian Pharmaceuticals industry which returned -46.2% over the past year.
Return vs Market: APHA underperformed the Canadian Market which returned 4.8% over the past year.
Shareholder returns
| APHA | Industry | Market | |
|---|---|---|---|
| 7 Day | 2.8% | -2.1% | -0.3% |
| 30 Day | -12.2% | -15.0% | -3.3% |
| 90 Day | -8.4% | -32.4% | -1.6% |
| 1 Year | -59.1%-59.1% | -46.2%-46.2% | 8.5%4.8% |
| 3 Year | 82.1%82.1% | 88.1%86.7% | 14.8%4.5% |
| 5 Year | n/a | 306.6%306.6% | 26.6%8.1% |
Price Volatility Vs. Market
How volatile is Aphria's share price compared to the market and industry in the last 5 years?
Simply Wall St News
10 months ago | Simply Wall St
Have Insiders Been Selling Aphria Inc (TSE:APHA) Shares?11 months ago | Simply Wall St
What You Must Know About Aphria Inc's (TSE:APHA) Financial Health11 months ago | Simply Wall St
Why Aphria Inc's (TSE:APHA) High P/E Ratio Isn't Necessarily A Bad ThingValuation
Is Aphria undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: APHA (CA$6.63) is trading below our estimate of fair value (CA$37.85)
Significantly Below Fair Value: APHA is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: APHA is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.
PE vs Market: APHA is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate APHA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: APHA is good value based on its PB Ratio (1x) compared to the CA Pharmaceuticals industry average (1.8x).
Next Steps
Future Growth
How is Aphria forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?
77.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: APHA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: APHA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: APHA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: APHA's revenue (37.2% per year) is forecast to grow faster than the Canadian market (5.6% per year).
High Growth Revenue: APHA's revenue (37.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: APHA's Return on Equity is forecast to be low in 3 years time (6%).
Next Steps
Past Performance
How has Aphria performed over the past 5 years?
23.4%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: APHA is unprofitable, but has reduced losses over the past 5 years at a rate of 23.4% per year.
Accelerating Growth: Unable to compare APHA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: APHA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (15.6%).
Return on Equity
High ROE: APHA has a negative Return on Equity (-1.21%), as it is currently unprofitable.
Return on Assets
ROA vs Industry: APHA is currently unprofitable, so its Return on Assets is negative.
Return on Capital Employed
ROCE Improving: APHA is currently unprofitable, so its Return on Capital Employed is negative.
Next Steps
Financial Health
How is Aphria's financial position?
Financial Position Analysis
Short Term Liabilities: APHA's short term assets (CA$735.9M) exceeds its short term liabilities (CA$123.0M)
Long Term Liabilities: APHA's short term assets (735.9M) exceeds its long term liabilities (555.3M)
Debt to Equity History and Analysis
Debt Level: APHA's debt to equity ratio (26.7%) is considered satisfactory
Reducing Debt: Insufficient data to determine if APHA's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Inventory Level: APHA has a high level of physical assets or inventory.
Debt Coverage by Assets: APHA's debt is covered by short term assets (assets are 1.6x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if APHA has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if APHA has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is Aphria's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: Unable to evaluate APHA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate APHA's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stable Dividend: Insufficient data to determine if APHA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if APHA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of APHA's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
Next Steps
Management
What is the CEO of Aphria's salary, the management and board of directors tenure and is there insider trading?
0.6yrs
Average management tenure
CEO
Irwin Simon (61yo)
0.6yrs
Tenure
CA$9,577,296
Compensation
Mr. Irwin D. Simon has been an Chairman of Aphria Inc. since December 27, 2018 and serves as its Interim Chief Executive Officer since March 01, 2019. Mr. Simon founded The Hain Celestial Group, Inc. a lea ...
CEO Compensation Analysis
Compensation vs. Market: Irwin has recently become CEO, making it difficult to compare their total compensation against companies of similar size in the Canadian market.
Compensation vs Earnings: Insufficient data to compare Irwin's compensation with company performance.
Management Age and Tenure
0.6yrs
Average Tenure
62.5yo
Average Age
Experienced Management: APHA's management team is not considered experienced ( 0.6 years average tenure), which suggests a new team.
Board Age and Tenure
0.9yrs
Average Tenure
58yo
Average Age
Experienced Board: APHA's board of directors are not considered experienced ( 0.9 years average tenure), which suggests a new board.
Insider Trading
Insider Buying: APHA insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 4,000 |
| Max Price | CA$6.20 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 1,500 |
| Max Price | CA$8.34 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 5,000 |
| Max Price | CA$9.46 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 2,000 |
| Max Price | CA$10.82 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 3,500 |
| Max Price | CA$6.40 |
| Entity | Individual |
| Shares | 7,500 |
| Max Price | CA$8.60 |
| Entity | Individual |
| Role | Senior Key Executive Special Advisor |
| Shares | 120,000 |
| Max Price | CA$8.55 |
| Entity | Individual |
| Role | Chief Financial Officer Chief Financial Officer |
| Shares | 3,300 |
| Max Price | CA$7.75 |
| Entity | Individual |
| Role | Senior Key Executive Special Advisor |
| Shares | 120,000 |
| Max Price | CA$8.58 |
| Entity | Individual |
| Shares | 117,200 |
| Max Price | CA$8.53 |
Ownership Breakdown
Management Team
Vic Neufeld (65yo)
Special Advisor
- Tenure: 0.6yrs
- Compensation: CA$1.00m
James Meiers
Chief Operating Officer of Aphria Leamington
- Tenure: 0.4yrs
Carl Merton
Chief Financial Officer
- Tenure: 3.8yrs
- Compensation: CA$1.37m
Gary Leong (54yo)
Chief Science Officer
- Tenure: 0yrs
John Sadler
Vice President of Investor Relations
- Tenure: 1.1yrs
Cole Cacciavillani (64yo)
Special Advisor
- Tenure: 0.6yrs
- Compensation: CA$457.89k
Christelle Gedeon
Chief Legal Officer
- Tenure: 1.3yrs
- Compensation: CA$1.61m
Hendrik Knopp
Managing Director of Aphria Germany
- Tenure: 0yrs
- Compensation: CA$1.70m
Irwin Simon (61yo)
Interim CEO & Chairman
- Tenure: 0.6yrs
- Compensation: CA$9.58m
Tim Purdie
Chief Information Officer & Chief Information Security Officer
- Tenure: 0.4yrs
Board Members
Walter Robb (65yo)
Independent Director
- Tenure: 0.5yrs
- Compensation: CA$33.17k
Dave Hopkinson (48yo)
Independent Director
- Tenure: 0.5yrs
- Compensation: CA$33.17k
Shawn Dym (39yo)
Independent Director
- Tenure: 2yrs
- Compensation: CA$342.11k
John Herhalt (62yo)
Lead Independent Director
- Tenure: 0.9yrs
- Compensation: CA$332.96k
Tom Looney (56yo)
Independent Director
- Tenure: 0.9yrs
- Compensation: CA$256.28k
Michael Serruya (55yo)
Independent Director
- Tenure: 0.9yrs
- Compensation: CA$250.12k
Renah Persofsky (60yo)
Independent Director
- Tenure: 2yrs
- Compensation: CA$423.88k
Irwin Simon (61yo)
Interim CEO & Chairman
- Tenure: 0.6yrs
- Compensation: CA$9.58m
Company Information
Aphria Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Aphria Inc.
- Ticker: APHA
- Exchange: TSX
- Founded:
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$1.668b
- Shares outstanding: 251.56m
- Website: https://aphriainc.com
Number of Employees
Location
- Aphria Inc.
- 245 Talbot Street West
- Suite 103
- Leamington
- Ontario
- N8H 3C4
- Canada
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| APHA | TSX (The Toronto Stock Exchange) | Yes | Common Shares | CA | CAD | Dec 2014 |
| APHA | NYSE (New York Stock Exchange) | Yes | Common Shares | US | USD | Dec 2014 |
| 10E | DB (Deutsche Boerse AG) | Yes | Common Shares | DE | EUR | Dec 2014 |
| 0UI4 | LSE (London Stock Exchange) | Yes | Common Shares | GB | CAD | Dec 2014 |
Biography
Aphria Inc. produces and sells medical cannabis in Canada and internationally. The company offers pharmaceutical-grade medical cannabis; and adult-use cannabis under the Solei, RIFF, Good Supply, and Broke ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/10/24 00:41 |
| End of Day Share Price | 2019/10/23 00:00 |
| Earnings | 2019/08/31 |
| Annual Earnings | 2019/05/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.